Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1181-1200 of 1,738 trials

Vitamin D for Low Testosterone in Men with Type 2 Diabetes

We are studying whether vitamin D supplements can help increase testosterone levels in men with type 2 diabetes. This trial compares the effects of vitamin D to a placebo.

Type 2 Diabetes≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesEndocrinologyInternal Medicine

Unilateral Retinoblastoma: Adjuvant Treatment Study

We are studying additional treatments for patients with unilateral retinoblastoma after eye removal. The goal is to understand how these treatments affect recovery and any potential side effects.

Retinoblastoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Ensifentrine for Non-Cystic Fibrosis Bronchiectasis

We are studying whether nebulized ensifentrine can help reduce lung flare-ups in people with non-cystic fibrosis bronchiectasis. The trial also examines its impact on respiratory symptoms and overall quality of life.

Non-Cystic Fibrosis Bronchiectasis>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

CRN04894 for Hormonal Imbalance

We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Scoliosis Surgery: Pooled Plasma vs. Crystalloid

We are studying whether pooled human plasma can reduce blood loss during spinal fusion surgery in children with scoliosis compared to a standard fluid. This trial aims to improve fluid management during surgery.

Neuromuscular ScoliosisAdolescent Idiopathic Scoliosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyPediatrics

Dilated Cardiomyopathy: Anakinra Treatment Study

We are investigating whether the medication Anakinra can improve heart function in people with dilated cardiomyopathy. This study compares Anakinra plus standard care to standard care alone.

Inflammatory Dilated Cardiomyopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Glioblastoma: Bevacizumab with Radiochemotherapy

We are studying a new treatment approach for patients with newly diagnosed glioblastoma to see if it improves survival and quality of life. The trial also evaluates safety and cognitive effects.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Head and Neck Cancer: Shortened Chemotherapy with Pembrolizumab

We are studying a shorter chemotherapy treatment combined with Pembrolizumab for patients with PD-L1-positive recurrent or metastatic head and neck cancer. The goal is to see if this approach is effective and safe compared to standard treatments.

Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

MDS and AML: Venetoclax with Azacitidine

We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.

Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab Study

We are comparing two treatment methods for patients with liver cancer to see if combining immune therapy with chemotherapy improves outcomes. The study will assess effectiveness, safety, and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Squamous Cell Carcinoma: Cetuximab with or without Paclitaxel

We are studying the effectiveness of cetuximab alone or with paclitaxel for patients with recurrent head and neck cancer after previous treatment. The goal is to see how these options affect survival and quality of life.

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: CAR-T Therapy vs. Rituximab

We are comparing a new CAR-T cell therapy with rituximab for patients with active rheumatoid arthritis that hasn't responded to other treatments. The goal is to see which therapy is safer and more effective.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesRheumatology

Rheumatoid Arthritis: AP1189 with Methotrexate

We are studying a new oral medication, AP1189, for people with early rheumatoid arthritis who haven't received other treatments. The goal is to see if it works better with methotrexate than methotrexate alone.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementRheumatology

Bladder Cancer: Sacituzumab Tirumotecan Study

We are investigating the effects of sacituzumab tirumotecan in individuals with bladder cancer. This study aims to see how well this treatment works compared to standard options.

Intermediate-risk Non-muscle Invasive Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology